ArticleVaccines2022
Estimation of Real-World Vaccination Effectiveness of mRNA COVID-19 Vaccines against Delta and Omicron Variants in Japan.
Article in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 3 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- Comparison of Omicron and Delta Variants of SARS-CoV-2: A Systematic Review of Current Evidence.Infectious disorders drug targets · 2024Pooled it
- Evaluation of Waning of SARS-CoV-2 Vaccine-Induced Immunity: A Systematic Review and Meta-analysis.JAMA network open · 2023Pooled it
- The Vaccine Efficacy Against the SARS-CoV-2 Omicron: A Systemic Review and Meta-Analysis.Frontiers in public health · 2022Pooled it
- Effect of Regdanvimab on Mortality in Patients Infected with SARS-CoV-2 Delta Variants: A Propensity Score-Matched Cohort Study.Infectious diseases and therapy · 2024Article
- Differentiating behavioral impact with or without vaccination certification under mass vaccination and non-pharmaceutical interventions on mitigating COVID-19.Scientific reports · 2024Article
- Effectiveness of the BNT162b2 and the CoronaVac vaccines and boosters in healthcare workers.Human vaccines & immunotherapeutics · 2023Article
- Population-Level Immunity for Transient Suppression of COVID-19 Waves in Japan from April 2021 to September 2022.Vaccines · 2023Article
- Mathematical modeling for Delta and Omicron variant of SARS-CoV-2 transmission dynamics in Greece.Infectious Disease Modelling · 2023Article
- Projection of COVID-19 Positive Cases Considering Hybrid Immunity: Case Study in Tokyo.Vaccines · 2023Article
- Using survey data to estimate the impact of the omicron variant on vaccine efficacy against COVID-19 infection.Scientific reports · 2023Article
- Vaccine Effect on Household Transmission of Omicron and Delta SARS-CoV-2 Variants.Journal of Korean medical science · 2023Article
- Estimation of mRNA COVID-19 Vaccination Effectiveness in Tokyo for Omicron Variants BA.2 and BA.5: Effect of Social Behavior.Vaccines · 2022Article
- Comparison of the safety and immunogenicity of the BNT-162b2 vaccine and the ChAdOx1 vaccine for solid organ transplant recipients: a prospective study.BMC infectious diseases · 2022Article
- COVID-19 forecasting using new viral variants and vaccination effectiveness models.Computers in biology and medicine · 2022Article
- COVID-19 Severity and Mortality after Vaccination against SARS-CoV-2 in Central Greece.Journal of personalized medicine · 2022Article
- OMICRON: Virology, immunopathogenesis, and laboratory diagnosis.The journal of gene medicine · 2022Review
- Did the Tokyo Olympic Games enhance the transmission of COVID-19? An interpretation with machine learning.Computers in biology and medicine · 2022Article
- Coronavirus disease 2019 transmission and symptoms in young children during the severe acute respiratory syndrome coronavirus 2 Delta variant and Omicron variant outbreaks.The Journal of international medical research · 2022Article
- Infection of the oral cavity with SARS-CoV-2 variants: Scope of salivary diagnostics.Frontiers in oral health · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A resurgence of COVID-19-positive cases has been observed in many countries in the latter half of 2021. The primary reasons for this resurgence are the waning immunity of vaccination after the second dose of vaccination and the changes in public behavior due to temporal convergence. The vaccination effectiveness for the omicron and delta variants has been reported from some countries, but it is still unclear for several other regions worldwide. Here, we numerically derived the effectiveness of vaccination for infection protection in individuals and populations against viral variants for the entire Japanese population (126 million). The waning immunity of vaccination for the delta variant of Japanese individuals was 93.8% (95% CI: 93.1−94.6%) among individuals <65 years of age and 95.0% (95% CI: 95.6−96.9%) among individuals ≥65 years of age. We found that waning immunity of vaccination in individuals >65 years of age was lower than in those <65 years of age, which may be attributable to human behavior and a higher vaccination rate among individuals >65 years of age. From the reported data of 25,187 positive cases with confirmed omicron variant in Tokyo in January 2022, the effectiveness of vaccination was also estimated at 62.1% (95% CI: 48−66%) compared to that of the delta variant. Derived effectiveness of vaccination would be useful to discuss the vaccination strategy for the booster shot, as well as the status of herd immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.